Dr. Deshpande is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
New Haven, CT 06510Phone+1 203-200-4822Fax+1 203-200-2099
Education & Training
Jacobi Medical Center/Albert Einstein College of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1998- Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1993 - 1995
- Jacobi Medical Center/Albert Einstein College of MedicineInternship, Internal Medicine, 1992 - 1993
University of Leeds School of MedicineClass of 1991
Certifications & Licensure
CT State Medical License 2001 - 2025
NV State Medical License 2000 - 2003
NY State Medical License 2001 - 2003
AZ State Medical License 1998 - 2002- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- David Fischer Teaching Award Yale Cancer Center
Clinical Trials
- Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma Start of enrollment: 2007 Mar 01
- Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers Start of enrollment: 2007 May 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors.Philippos Apolinario Costa, Arshia Arora, Yannelys Fernandez, Irvin Yi, Baylee Bakkila
Cancer. 2024-11-14 - 3 citationsA Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.Scott M Schuetze, Karla V Ballman, Rachel Heise, Kristen N Ganjoo, Elizabeth J Davis
Clinical Cancer Research. 2024-10-15 - 1 citationsUse of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.Hao Wu, Madina Sukhanova, Haiming Tang, Xinyan Lu, Minghao Zhong
Archives of Pathology & Laboratory Medicine. 2024-08-21
Press Mentions
Yale Cancer Center Shares Five Things You Need to Know About Sarcoma, a Rare CancerJuly 7th, 2021- New Haven Company's 'Orphan Drug' May Aid Fight Against Rare CancerFebruary 8th, 2021
- Connecticut Gets Slight Boost in Vaccine Supply, but Distributors Say They Need More DosesJanuary 28th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
